TYK Medicines, Inc (02410)
TYK Medicines, Inc., a clinical-stage biopharmaceutical company, research, development and commercialization of pharmaceutical products. Its lead product candidate is TY-9591, a third-generation epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor for the treatment of brain metastases from non-small cell lung cancer (NSCLC) with EGFR mutations, and in locally advanced or metastatic NSCLC with EGFR L858R mutatio
CS Hotline: +852 3018 4526
Trading days: 24 hours | Non-trading days: 9:00-18:00
